Title of Invention	2-AMINO-4-HETEROARYLETHYL THIAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
Abstract	ABSTRACT 982/CHENP/2004 "2-ainino-4-heteroarylethyl-thiazoline derivatives and pharmaceutical composition including the same" The present invention relates to the use of 2-aniino-4-heteroarytethyl-thiazolme derivatives of formula (I) in which Het represents thienyle, pyrimidyle, pyridyle or thiazolyle radical or a pharmaceutically acceptable salts thereof as inhibitors of inducible NO-synthase.

Full Text

CLAIMS 1 Compound of formula (1) wherin Het represents a 2-thienyle, 3-thienyle, 2-pyrimidyle, 5-pyrimidyle, 2-pyridyle, 3-pyridy!e, 4-p\'ridyle, 2-thiazolyle, 4-ihiazolyle or 5-thiazolyle radical the racemic mixtures, enantiomers, diastereoisomers thereof and mixtures thereof, tautomers thereof and pharmaceutically acceptable salts thereof. 2 Compound according to claim 1, wherein the compound of formula {!) is chosen from the following compounds : 4-(2-pyridin-2-y!ethyl)-4,5-dihydro-1.3-thiazol-2-y]amine 4-(2-pyridin-3-ylethyl)-4.5-dihydro-1.3-thiazol-2-ylamine 4-(2-pyridin-4-ylelhyl)-4.5-dihydro-l,3-thiazol-2-ylamine 4-(2-thien-3-y]ethyl)-4.5-dihydro-1.3-thiazol-2-ylamine the racemic mixtures, enantiomers, diastereoisomers thereof and mixtures thereof, tautomers thereof and pharmaceutically acceptable salts thereof. 3 Compound according to claims! to 2, wherein the compound of formula (I) is chosen from the following compounds : (+)-{4R)-4-(2-pyridin-2-ylethyl)-4.5-dihydro-1.3-thiazol-2-ylamme (+)-(4R)-4-(2-pyridm-3-y\ethy\)-4.5-dihydro-\.3-thiazol-2-ylaTnine (+)-{4R)-4-{2-pyridin-4-ylethy])-4,5-dihydro-1.3-thiazoi-2-yiamine (4R)-4-(2-thien-3-ylethyi)-4.5-dihydro-1.3-thiazol-2-yiam!ne the tautomers thereof as well as the pharmaceutically acceptable salts thereof. 4 Compound according to claims 1 to 3, for its application as a medicinal product. 5 Pharmaceutical composition wherein it contains, in a phaiTnaceutically acceptable medium, a compound defined according to claims 1 to 3. 6 Medicinal product according to claims 4 wherin it contains at least one compound defined accordint to claim I to 3 for its therapeutic application in the treatment of diseases in which an abnormal production of nitric oxyde (NO) by induction of inducible NO-synthase (NOS-2) is involved. 7 Medicinal product according to claim 4 wherein it contains at least a compound defined according to claims 1 to 3 for its therapeutic application in the treatment of the Parkinson's disease. S Method for the preparation of the compounds of formula (!) such as defined in claim 1, comprising the step of cyclizing a derivative of formula: wherein Het has the same meanings as in claim 1, and optionally converting the product into a pharmaceutically acceptable salt. 9 Method for the preparation according to claim 8 wherein the cyclization is carried out in an acid medium at a temperature of about 100°C. 10 Method for the preparation according to claim 9 wherein the acid medium is preferably 6N hydrochloric acid. 11 Method for the preparation of compounds of formula (11) such as defined in claim S and in which Het has the same meaning as in claim 1, comprising the step of reacting a compound of formula (Ila) wherein Ra is a protecting group of the amine formation and Rb is a protecting group of the /5-amino alcohol function with the action of a boron derivative and X-Het in order to obtain a compound of formula (lib) which is subjected to the action of a deprotecting agent in order to obtain a compound of formula (lie) which is subjected to the action of the r^r;-butylisothiocyanate in order to obtain a compound of formula {II) WE CLAIM: 1. A compound of the fonnula (I) wherein Het is 2-thienyl, 3-thienyl, or a racemic mixture, an enantiomer, a diastereoisomer or a mixture thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, 2. The compound according to claim 1, wherein the compound of fonnula (I) is 4-(2-thien-3-ylethyl)-4.5-dihydro-1,3-thiazol-2-ylamine, or a racemic mixture, an enantiomer, a diastereoisomer or a mixture thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof 3. The compound according to claim 1, wherein the compound of formula (I) is (4R)-4-(2-thien-3-ylethyl)-4,5-dihydro-l,3-thiazol-2-ylamine, or a tautomer thereof or a pharmaceutically acceptable salt thereof. 4. A pharmaceutical composition comprising, as active ingredient, at least one compound of formula (l): wherein Het is 2-thienyl, 3-lhienyl, or a racemic mixture, an enantiomer, a diastereoisomer or a mixture thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier. 5. The composition according to claim 4, wherein the compound of formula (I) is 4-(2-thien-3-yiethyI)-4,5-dihydro-l,3-thiazoi-2-yiamine, or a racemic mixture, an enantiomer, a diastereoisomer or a mixture thereof, a tautomer thereof, or a pharmaceutically acceptable saU thereof 6. The composition according to claim 4, wherem the compound of formula (I) is (4R)-4-(2-thien-3-ylethyl)-4,S-dihydro-l,3-thiazol-2-ylamine, or a tautomer thereof or a pharmaceutically acceptable salt thereof

Documents:

0982-chenp-2004 abstract-duplicate.pdf

0982-chenp-2004 abstract.pdf

0982-chenp-2004 claims-duplicate.pdf

0982-chenp-2004 claims.pdf

0982-chenp-2004 correspondence-others.pdf

0982-chenp-2004 correspondence-po.pdf

0982-chenp-2004 description (complete)-duplicate.pdf

0982-chenp-2004 description (complete).pdf

0982-chenp-2004 form-1.pdf

0982-chenp-2004 form-18.pdf

0982-chenp-2004 form-26.pdf

0982-chenp-2004 form-3.pdf

0982-chenp-2004 form-5.pdf

0982-chenp-2004 pct.pdf

0982-chenp-2004 petition.pdf

982.jpg